letter
editor
ard
sar
cytokin
mediat
treatment
implic
dear
sir
wish
draw
reader
attent
possibl
sever
pulmonari
failur
sever
adult
respiratori
syndrom
sar
associ
mortal
rate
may
secondari
overwhelm
inflammatori
respons
precipit
urbani
sarscoronaviru
sarscov
infect
may
amen
cytokinetarget
therapi
soon
outbreak
diseas
peiri
et
al
describ
sar
patient
progress
short
time
frame
mean
day
sever
pulmonari
diseas
uncompl
case
recov
wherea
patient
deterior
within
short
followup
period
one
die
hand
monitor
serum
antibodi
show
seroconvers
occur
day
instanc
patient
immun
defens
effect
interven
around
day
therefor
onset
symptom
day
critic
window
activ
treatment
cumul
find
sar
autopsi
materi
refer
other
describ
spectrum
pulmonari
patholog
rang
desquam
pneumocyt
alveolar
space
associ
necrot
inflammatori
debri
proteinac
exud
hyalin
membran
format
intraalveolar
interstiti
mononuclear
cell
infiltr
accumul
multinucl
syncyti
cell
macrophag
follow
latestag
fibroblast
mesenchym
prolifer
patholog
progress
similar
seen
acut
respiratori
distress
syndrom
ard
induc
caus
substanti
bodi
evid
shown
inflammatori
cytokin
play
central
role
ard
donnelli
et
al
found
signific
level
macrophag
migrat
inhibitori
factor
mif
alveolar
space
ard
patient
could
activ
releas
tumor
necrosi
factor
alpha
tnfa
interleukin
level
tnfa
effect
attenu
antimif
sever
report
also
demonstr
domin
role
mifnfkbtnfa
cascad
ard
schemat
shown
fig
earli
evid
role
cytokin
physiopatholog
sar
ng
et
al
show
pediatr
popul
sar
patient
markedli
elev
level
circul
level
may
suggest
involv
activ
pathway
studi
mild
elev
cytokin
tnfa
chines
literatur
base
larger
number
patient
differ
age
highlight
import
interleukin
indic
signific
elev
tnfa
late
stage
diseas
system
lungspecif
data
thu
experi
must
pursu
investig
role
inflammatori
cytokin
sar
propos
therapi
target
tnfa
interleukin
consid
effect
treatment
probabl
institut
earli
pathophysiolog
chang
becom
overwhelm
may
also
help
control
extrapulmonari
manifest
sar
patient
may
cytokinerel
report
intravascular
coagul
vivo
vitro
evid
target
cytokin
state
may
benefit
sar
patient
may
repres
treatment
establish
multipurpos
drug
corticosteroid
ribavirin
new
imidazol
deriv
recent
design
potent
anti
tnfa
compound
central
aspect
treatment
may
involv
target
therapi
indic
diseas
progress
furthermor
small
grow
famili
drug
shown
exhibit
inhibitori
effect
macrophag
migrat
inhibitori
factor
mif
tnfa
monoclon
antibodi
solubl
receptor
tnfa
infliximab
etanercept
commonli
use
treatment
chronic
inflammatori
condit
crohn
diseas
rheumatoid
arthriti
inhibitor
tnf
translat
shown
effect
protect
anim
sever
acut
inflammatori
disord
promis
result
studi
inhibitor
nfkb
also
exploit
basic
represent
cytokin
activ
pathway
ard
lung
possibl
area
therapeut
target
indic
fig
summari
applic
new
clinic
test
anticytokin
consid
manag
acut
phase
sar
sinc
proper
trial
antimifnfkbtnf
agent
treat
ard
would
argu
futur
new
sar
epidem
would
present
excel
opportun
scientif
clinic
commun
